Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PHILADELPHIA, Jan. 02, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT (8:15 p.m. ET) in San Francisco, CA.
Related news for (CABA)
- Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
- Today’s Top Performers: MoBot’s Market Review 10/09/25 12:00 PM
- 24/7 Market News Snapshot 09 October, 2025 – Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA)
- MoBot’s Stock Market Highlights – 08/13/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 08/13/25 11:00 AM
